Yesterday, a Director at Natera (NASDAQ: NTRA), Steuart John, sold shares of NTRA for $15.77K.
In addition to Steuart John, 2 other NTRA executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Natera’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $62.34 million and GAAP net loss of $32.87 million. In comparison, last year the company earned revenue of $46.9 million and had a GAAP net loss of $35.96 million. Currently, Natera has an average volume of 122.4K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $16.33, reflecting a -28.4% downside.
The insider sentiment on Natera has been negative according to 12 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception, and Non-Invasive Paternity Testing.
